Home›Research›Compare›Retatrutide vs Tirzepatide
Peptide ComparisonRetatrutide vs Tirzepatide
Both are Metabolic peptides.
Retatrutide
GLP-3
Half-life: ~6 days
138 providers listed
Tirzepatide
Dual GLP-1
Half-life: ~5 days (once-weekly dosing)
577 providers listed
Tirzepatide is FDA-approved, while Retatrutide is investigational — the clearest structural difference between them.
Retatrutide
Half-life
~6 days
Tirzepatide
Half-life
~5 days (once-weekly dosing)
| Your goal | Better option |
|---|---|
| Further along in FDA review | Tirzepatide |
| Less frequent dosing (longer half-life) | Tirzepatide |
| Lower typical price per mg | Tirzepatide |
| More provider options (138 vs 577) | Tirzepatide |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Retatrutide
Tirzepatide
Retatrutide
Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Revi…
Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes.
Design of the TRIUMPH phase 3 clinical trial programme for retatrutide in obesity and cardiometabolic disease
Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial
+6 more
Tirzepatide
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)
Tirzepatide Once Weekly for the Treatment of Obesity
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Real-World Effectiveness of Tirzepatide in Japanese Patients with Type 2 Diabetes: A Multicenter Retrospectiv…
+5 more
About Retatrutide
Triple GIP/GLP-1/glucagon receptor agonist; targets three pathways for synergistic fat reduction
About Tirzepatide
Tirzepatide is a dual agonist of both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP receptor activation adds a complementary mechanism to GLP-1 agonism — enhancing insulin secretion, reducing glucagon, and modulating adipose tissue metabolism independently of GLP-1 pathways. The combination produces greater average weight reduction in clinical trials than selective GLP-1 agonists at comparable doses.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Retatrutide
Class-based (investigational)
Tirzepatide
Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).
Source: FDA label
FDA prescribing protocols track HbA1c and fasting glucose for glycemic response, calcitonin for thyroid C-cell risk (black box warning), and lipase for pancreatitis screening. Baseline renal and hepatic panels are standard.
Retatrutide
Tirzepatide
Where to source these peptides
Retatrutide
138 listed
Browse directory →
Providers offeringTirzepatide
577 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Metabolic Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated October 27, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Retatrutide vs Tirzepatide — Per-mg Price Comparison. Retrieved October 27, 2026, from https://peptidebase.io/peptides/compare/retatrutide/tirzepatide